Biodexa Director Holds Long‑Term Option Amid ADR Restructure – Market Cautiously Optimistic.
Insider option deal at Biodexa Pharma shows board confidence, but weak market sentiment and low valuation keep investors cautious about long‑term upside.
2 minutes to read